Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Wenzler

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 18, 2015
Editorial commentary: improving prescribers to advance antimicrobial stewardshipEric Wenzler, Keith A Rodvold, Larry H Danziger
BMC Nephrology|October 10, 2024
Edoxaban pharmacokinetics during in vitro continuous renal replacement therapyEric Wenzler, Kaitlyn Dalton, Lauren Andrews, et al.
Hospital Pharmacy|April 26, 2017
Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in WaterKevin Meyer, Maressa Santarossa, Larry H Danziger, et al.
Open Forum Infectious Diseases|April 13, 2022
Overcoming <i>Stenotrophomonas maltophilia</i> Resistance for a More Rational Therapeutic ApproachRavina Kullar, Eric Wenzler, Jose Alexander, et al.
International Journal of Antimicrobial Agents|November 27, 2019
Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysisJovan Borjan, Kevin A Meyer, Ryan K Shields, et al.
Open Forum Infectious Diseases|October 30, 2019
Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With <i>Enterobacteriaceae</i> Bloodstream InfectionsMelissa Santibañez, Kristen Bunnell, Amanda Harrington, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|November 27, 2020
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory DiseaseEric Wenzler, Monaz H Engineer, Maidah Yaqoob, et al.
Clinical Pharmacokinetics|November 18, 2021
Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement TherapyEric Wenzler, David Butler, Xing Tan, et al.
Clinical Microbiology Reviews|May 27, 2016
Inhaled Antibiotics for Gram-Negative Respiratory InfectionsEric Wenzler, Dustin R Fraidenburg, Tonya Scardina, et al.
Microbiology Spectrum|June 1, 2022
Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline SusceptibilityTaylor Abbey, Alesia Vialichka, Michele Jurkovic, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 18, 2015
Editorial commentary: improving prescribers to advance antimicrobial stewardshipEric Wenzler, Keith A Rodvold, Larry H Danziger
BMC Nephrology|October 10, 2024
Edoxaban pharmacokinetics during in vitro continuous renal replacement therapyEric Wenzler, Kaitlyn Dalton, Lauren Andrews, et al.
Hospital Pharmacy|April 26, 2017
Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in WaterKevin Meyer, Maressa Santarossa, Larry H Danziger, et al.
Open Forum Infectious Diseases|April 13, 2022
Overcoming <i>Stenotrophomonas maltophilia</i> Resistance for a More Rational Therapeutic ApproachRavina Kullar, Eric Wenzler, Jose Alexander, et al.
International Journal of Antimicrobial Agents|November 27, 2019
Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysisJovan Borjan, Kevin A Meyer, Ryan K Shields, et al.
Open Forum Infectious Diseases|October 30, 2019
Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With <i>Enterobacteriaceae</i> Bloodstream InfectionsMelissa Santibañez, Kristen Bunnell, Amanda Harrington, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|November 27, 2020
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory DiseaseEric Wenzler, Monaz H Engineer, Maidah Yaqoob, et al.
Clinical Pharmacokinetics|November 18, 2021
Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement TherapyEric Wenzler, David Butler, Xing Tan, et al.
Clinical Microbiology Reviews|May 27, 2016
Inhaled Antibiotics for Gram-Negative Respiratory InfectionsEric Wenzler, Dustin R Fraidenburg, Tonya Scardina, et al.
Microbiology Spectrum|June 1, 2022
Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline SusceptibilityTaylor Abbey, Alesia Vialichka, Michele Jurkovic, et al.
Pageof 8